Abstract Library

#4662 A novel hormone based anti-SSTR anti-CD3 T-cell engager for the treatment of neuroendocrine tumours

Introduction: Somatostatin receptor 2 (SSTR2) is overexpressed in well-differentiated NETs.

Conference:

Presenting Author: Pelle E

Authors: Pelle E, Cives M, Chaoul N, d'Angelo G, Medina E,

Keywords: T-cell engager, immunotherapy, tumouroids,

#4285 Predictive biomarkers for immunotherapy efficacy in neuroendocrine neoplasms

Introduction: The application of immunotherapy in NENs is still in its early stages. Identifying reliable predictive biomarkers of efficacy is critical for research, enabling better selection of patients who are more likely to respond to immunotherapy and improving treatment success rates.

Conference:

Presenting Author: Liang Y

Authors: Liang Y, Sun Z, Jia X, Chen J,

Keywords: immunotherapy, biomarker, neuroendocrine neoplasm,

#4088 Ex vivo expansion of TILs from panNET liver metastasis: In search of novel adoptive transfer strategies for the treatment of NETs

Introduction: It is unknown whether tumor infiltrating lymphocytes (TILs) from NETs may be an effective treatment in patients with NETs.

Conference:

Presenting Author: Chaoul N

Authors: Chaoul N, d'Angelo G, Giglio A, Mandriani B, Matrella M,

Keywords: panNET, TILs, adoptive T cell therapy, neoantigen-reactive TILs,

#3883 Immune landscape in mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN)

Introduction: A mixed neuroendocrine-non neuroendocrine neoplasm (MiNEN) is a novel defined rare entity, made up of two morphologically distinct neoplastic components; one neuroendocrine type (NEN), and the other one non-neuroendocrine type (nNEN). Neuroendocrine differentiation of tumors is thought to influence the tumor microenvironment (TME) through the secretion of various hormones or growth factors.

Conference:

Presenting Author:

Authors: Di Mauro A, Ferrara G, Iervolino D, Scognamiglio G, Clemente O,

Keywords: mixed neuroendocrine, neuroendocrine, tumor microenvironment, immunotherapy, biomarker,

#3758 A novel hormone-based anti-SSTR T-cell engager for the treatment of neuroendocrine tumors

Introduction: Somatostatin receptors (SSTRs) are overexpressed by well-differentiated neuroendocrine tumors (NETs).

Conference:

Presenting Author: Pelle E

Authors: Pelle E, Cives M, Medina E, Mason C, Snedal S,

Keywords: Bispecific T cell Engagers, CD3, SSTR, TILs, Immunotherapy,